License and Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2012

License, Collaboration and Other Revenue

In accordance with these agreements, we recognized license, collaboration and other revenue as follows (in thousands):

		Year Ended December 31,
Partner	Agreement	2012		2011		2010
Roche	PEGASYS® and MIRCERA®	$	7,146	$	5,131	$	5,131
Baxter Healthcare	Hemophilia		6,238		5,646		1,701
Amgen, Inc.	Neulasta®		5,000		5,000		833
Bayer Healthcare LLC	BAY41-6551 (Amikacin Inhale)		2,971		2,992		3,300
Affymax, Inc.	OMONTYS®		2,829		3,838		1,867
AstraZeneca AB	Naloxegol (NKTR-118) and naloxegol fixed-dose combination program (NKTR-119)		59		2,496		107,854
Other			5,884		11,186		3,686
License, collaboration and other revenue		$	30,127	$	36,289	$	124,372